- Home
- ALLO vs IIIV Comparison
ALLO vs IIIV Comparison
Compare ALLO & IIIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLO | IIIV |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | 152 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.4M | 434.2M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ALLO | IIIV |
|---|---|---|
| Price | $2.02 | $19.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | $8.35 | ★ $33.20 |
| AVG Volume (30 Days) | ★ 8.0M | 330.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.05 |
| Revenue Next Year | $142,416.42 | $8.07 |
| P/E Ratio | ★ N/A | $236.56 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.99 | $18.47 |
| 52 Week High | $4.46 | $33.97 |
Technical Indicators
Market Signals| Indicator | ALLO | IIIV |
|---|---|---|
| Relative Strength Index (RSI) | 38.70 | 33.37 |
| Support Level | $1.85 | N/A |
| Resistance Level | $2.71 | $23.62 |
| Average True Range (ATR) | 0.14 | 1.13 |
| MACD | -0.01 | -0.40 |
| Stochastic Oscillator | 8.33 | 9.04 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About IIIV i3 Verticals Inc.
i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.